O-47 XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients (p) with poor survival with gemcitabine (gem)/cisplatin (cis)

Authors :: Vicente Alberola
Rafael Rosell
Miguel Taron
Bartomeu Massuti
Ramon de las
Pedro Mendez
Ramon Garcia
Carlos Camps
Carme Sarries
Amelia Insal
Source :: Lung Cancer. 41:S17
Publication Year :: 2003
Publisher :: Elsevier BV, 2003.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
Cisplatin
Cancer Research
medicine.medical_specialty
business.industry
non-small cell lung cancer (NSCLC)
medicine.disease
Gemcitabine
Internal medicine
medicine
business
medicine.drug

Full Text Access

Tools